CALA — Calithera Biosciences Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
U.S. STOCKS ON THE MOVE-American Airlines, Travelers, Chinese tech ADRs
SVB Leerink upgrades Calithera to "buy" on potential of cancer drugs
Calithera Biosciences Inc reports results for the quarter ended in September - Earnings Summary
Brief: Calithera Biosciences Reports Third Quarter 2021 Financial Results And Recent Highlights
Calithera Biosciences Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Calithera Presents Interim Data From Phase 1B Trial Of Arginase Inhibitor CB-280 In Cystic Fibrosis At NACFC 2021
Brief: Calithera Expands Oncology Pipeline With Acquisition Of Two Clinical-Stage Assets From Takeda Pharmaceuticals
Calithera Biosciences up as Incyte to pay settlement amount for cancer therapy
Brief: Calithera Biosciences Says On September 14, 2021, Co Entered Into A Settlement Agreement And Release With Incyte
Calithera Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Calithera Biosciences Q2 Revenue $3.0 Million
Calithera Biosciences Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Final Data From Calithera Biosciences’ Phase 2 Cantata Study In Renal Cell Carcinoma Presented At 2021 Asco Annual Meeting
U.S. RESEARCH ROUNDUP- Agiliti, Costco Wholesale, Treace Medical Concepts
Brief: Calithera Biosciences And Antengene Enter Worldwide License Agreement For Development & Commercialization Of Cb-708
Calithera Biosciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Calithera Biosciences Reports First Quarter 2021 Financial Results And Recent Highlights
Calithera Biosciences Inc expected to post a loss of 28 cents a share - Earnings Preview
Brief: Calithera Biosciences Reports Fourth Quarter 2020 Financial Results And Recent Highlights